Sodium-coupled monocarboxylate transporter 1 and 2 (SLC5A8 and SLC5A12) (SLC5A8/SLC5A12)

SLC5A8 (SMCT1) and SLC5A12 (SMCT2) are members of the solute carrier family 5 that function as sodium-coupled transporters for monocarboxylates, including lactate, pyruvate, and short-chain fatty acids like butyrate [NIH, 2008; GeneCards]. SLC5A8 is a high-affinity transporter primarily expressed in the colon and kidney, where it acts as a tumor suppressor [NIH, 2026; Cancer Genetics]. Its expression is frequently silenced by DNA methylation in various cancers, such as colon and thyroid cancer, which prevents the entry of histone deacetylase (HDAC) inhibitors like butyrate that would otherwise induce apoptosis [NIH, 2011; Cancer Genetics]. In contrast, SLC5A12 is a low-affinity transporter expressed in the small intestine, kidney, and on the surface of CD4+ T cells [Wikipedia; University of Birmingham]. In inflammatory environments, SLC5A12-mediated lactate uptake by T cells triggers metabolic reprogramming and the production of pro-inflammatory cytokines like IL-17 [IUPHAR/BPS Guide to Pharmacology; NIH, 2024]. This makes SLC5A12 a promising therapeutic target for treating autoimmune diseases like rheumatoid arthritis and Sjögren's disease [NIH, 2024]. Pharmacological modulation of these transporters includes the use of non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen as blockers, or epigenetic agents like 5-azacytidine to restore SLC5A8 expression in tumors [Wikipedia; NIH, 2010; NIH, 2008]. Additionally, SLC5A8 has been explored as a delivery mechanism for drugs like dichloroacetate to enhance their anti-tumor efficacy [NIH, 2010]. Together, these transporters play critical roles in maintaining metabolic homeostasis and modulating immune and apoptotic pathways [NIH, 2008; ResearchGate].

Other names

SMCT1SMCT2Solute carrier family 5 member 8Solute carrier family 5 member 12AITApical iodide transporterElectrogenic sodium monocarboxylate cotransporterElectroneutral sodium monocarboxylate cotransporter

SLC5A8 and SLC5A12 function as sodium-coupled transporters for monocarboxylates like lactate and butyrate. SLC5A8 acts as a tumor suppressor by facilitating the entry of histone deacetylase (HDAC) inhibitors (e.g., butyrate) into cells, while SLC5A12 promotes inflammation by mediating lactate uptake in CD4+ T cells, leading to pro-inflammatory cytokine production [NIH, 2008; NIH, 2024].